 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- AC0682 / Accutar Biotech
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Apr 11, 2024
P1, N=21, Terminated, Sponsor: Accutar Biotechnology Inc
N=30 --> 21 | Trial completion date: Dec 2024 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Apr 2024; Voluntarily terminate the study since the sponsor's development strategy was adjusted.
- | AC0682 / Accutar Biotech
Trial completion date, Trial primary completion date, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Apr 4, 2024
P1, N=30, Active, not recruiting, Sponsor: Accutar Biotechnology Inc
N=30 --> 21 | Trial completion date: Dec 2024 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Apr 2024; Voluntarily terminate the study since the sponsor's development strategy was adjusted. Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
- AC676 / Accutar Biotech
A Phase I study evaluating AC676, an innovative BTK chimeric degrader, in patients with relapsed and refractory B-cell malignancies (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_5222;
Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024 Abstract is embargoed at this time.
- AC699 / Accutar Biotech
A Phase 1 trial evaluating AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_3874;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- AC699 / Accutar Biotech
AC699-001, a first in human Phase 1 trial utilizing a novel estrogen receptor chimeric degrader in patients with advanced or metastatic breast cancer (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1268;
P1
Several ER-directed therapies have been developed to antagonize the oncogenic ER function, including Selective ER Degraders (SERDs) such as fulvestrant which is approved to treat patients with advanced or metastatic breast cancer...Enrollment began in December 2022 with five sites in the United States planned. NCT05654532.
- || AC0682 / Accutar Biotech
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 26, 2023
P1, N=6, Active, not recruiting, Sponsor: Accutar Biotechnology Inc
NCT05654532. Recruiting --> Active, not recruiting | N=150 --> 6 | Trial primary completion date: Jul 2023 --> Dec 2023
- || AC0176 / Accutar Biotech
Enrollment closed, Enrollment change, Metastases: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Oct 26, 2023
P1, N=8, Active, not recruiting, Sponsor: Accutar Biotechnology Inc
Recruiting --> Active, not recruiting | N=150 --> 6 | Trial primary completion date: Jul 2023 --> Dec 2023 Recruiting --> Active, not recruiting | N=150 --> 8
- || AC0682 / Accutar Biotech
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Oct 25, 2023
P1, N=30, Active, not recruiting, Sponsor: Accutar Biotechnology Inc
Recruiting --> Active, not recruiting | N=150 --> 8 Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
- || AC0176 / Accutar Biotech
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Oct 23, 2023
P1, N=36, Active, not recruiting, Sponsor: Accutar Biotechnology Inc
Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Jan 2024 Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Apr 2024
- ||| AC0176 / Accutar Biotech
Enrollment open, Metastases: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Aug 25, 2023
P1, N=150, Recruiting, Sponsor: Accutar Biotechnology Inc
Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Apr 2024 Not yet recruiting --> Recruiting
- ||| AC676 / Accutar Biotech
Enrollment open: A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies (clinicaltrials.gov) - Aug 14, 2023
P1, N=60, Recruiting, Sponsor: Accutar Biotechnology Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| AC676 / Accutar Biotech
New P1 trial: A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies (clinicaltrials.gov) - Mar 22, 2023
P1, N=60, Not yet recruiting, Sponsor: Accutar Biotechnology Inc
- ||| AC0176 / Accutar Biotech
New P1 trial, Metastases: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 6, 2023
P1, N=150, Not yet recruiting, Sponsor: Accutar Biotechnology Inc
- ||| AC699 / Accutar Biotech
Enrollment open, Metastases: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 4, 2023
P1, N=60, Recruiting, Sponsor: Accutar Biotechnology Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| AC699 / Accutar Biotech
New P1 trial, Metastases: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 16, 2022
P1, N=60, Not yet recruiting, Sponsor: Accutar Biotechnology Inc
- | AC0682 / Accutar Biotech
Trial primary completion date, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Dec 13, 2022
P1, N=30, Recruiting, Sponsor: Accutar Biotechnology Inc
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2022 --> Jun 2023
- ||| AC0682 / Accutar Biotech
Enrollment open, Metastases: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 28, 2022
P1, N=150, Recruiting, Sponsor: Accutar Biotechnology Inc
Trial primary completion date: Sep 2022 --> Jun 2023 Not yet recruiting --> Recruiting
- ||| AC0682 / Accutar Biotech
New P1 trial, Metastases: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 5, 2022
P1, N=150, Not yet recruiting, Sponsor: Accutar Biotechnology Inc
- || AC0176 / Accutar Biotech
Enrollment open, Metastases: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 6, 2022
P1, N=36, Recruiting, Sponsor: Accutar Biotechnology Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || AC0176 / Accutar Biotech
New P1 trial, Metastases: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Feb 16, 2022
P1, N=36, Not yet recruiting, Sponsor: Accutar Biotechnology Inc
- || AC0682 / Accutar Biotech
Enrollment open, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Jan 3, 2022
P1, N=30, Recruiting, Sponsor: Accutar Biotechnology Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AC0682 / Accutar Biotech
New P1 trial, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Oct 17, 2021
P1, N=42, Not yet recruiting, Sponsor: Accutar Biotechnology Inc